Cargando…

Abrogation of contaminating RNA activity in HIV-1 Gag VLPs

BACKGROUND: HIV-1 Gag virus like particles (VLPs) used as candidate vaccines are regarded as inert particles as they contain no replicative nucleic acid, although they do encapsidate cellular RNAs. During HIV-1 Gag VLP production in baculovirus-based expression systems, VLPs incorporate the baculovi...

Descripción completa

Detalles Bibliográficos
Autores principales: Valley-Omar, Ziyaad, Meyers, Ann E, Shephard, Enid G, Williamson, Anna-Lise, Rybicki, Edward P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204299/
https://www.ncbi.nlm.nih.gov/pubmed/21975161
http://dx.doi.org/10.1186/1743-422X-8-462
_version_ 1782215201317191680
author Valley-Omar, Ziyaad
Meyers, Ann E
Shephard, Enid G
Williamson, Anna-Lise
Rybicki, Edward P
author_facet Valley-Omar, Ziyaad
Meyers, Ann E
Shephard, Enid G
Williamson, Anna-Lise
Rybicki, Edward P
author_sort Valley-Omar, Ziyaad
collection PubMed
description BACKGROUND: HIV-1 Gag virus like particles (VLPs) used as candidate vaccines are regarded as inert particles as they contain no replicative nucleic acid, although they do encapsidate cellular RNAs. During HIV-1 Gag VLP production in baculovirus-based expression systems, VLPs incorporate the baculovirus Gp64 envelope glycoprotein, which facilitates their entry into mammalian cells. This suggests that HIV-1 Gag VLPs produced using this system facilitate uptake and subsequent expression of encapsidated RNA in mammalian cells - an unfavourable characteristic for a vaccine. METHODS: HIV-1 Gag VLPs encapsidating reporter chloramphenicol acetyl transferase (CAT) RNA, were made in insect cells using the baculovirus expression system. The presence of Gp64 on the VLPs was verified by western blotting and RT-PCR used to detect and quantitate encapsidated CAT RNA. VLP samples were heated to inactivate CAT RNA. Unheated and heated VLPs incubated with selected mammalian cell lines and cell lysates tested for the presence of CAT protein by ELISA. Mice were inoculated with heated and unheated VLPs using a DNA prime VLP boost regimen. RESULTS: HIV-1 Gag VLPs produced had significantly high levels of Gp64 (~1650 Gp64 molecules/VLP) on their surfaces. The amount of encapsidated CAT RNA/μg Gag VLPs ranged between 0.1 to 7 ng. CAT protein was detected in 3 of the 4 mammalian cell lines incubated with VLPs. Incubation with heated VLPs resulted in BHK-21 and HeLa cell lysates showing reduced CAT protein levels compared with unheated VLPs and HEK-293 cells. Mice inoculated with a DNA prime VLP boost regimen developed Gag CD8 and CD4 T cell responses to GagCAT VLPs which also boosted a primary DNA response. Heating VLPs did not abrogate these immune responses but enhanced the Gag CD4 T cell responses by two-fold. CONCLUSIONS: Baculovirus-produced HIV-1 Gag VLPs encapsidating CAT RNA were taken up by selected mammalian cell lines. The presence of CAT protein indicates that encapsidated RNA was expressed in the mammalian cells. Heat-treatment of the VLPs altered the ability of protein to be expressed in some cell lines tested but did not affect the ability of the VLPs to stimulate an immune response when inoculated into mice.
format Online
Article
Text
id pubmed-3204299
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32042992011-10-30 Abrogation of contaminating RNA activity in HIV-1 Gag VLPs Valley-Omar, Ziyaad Meyers, Ann E Shephard, Enid G Williamson, Anna-Lise Rybicki, Edward P Virol J Research BACKGROUND: HIV-1 Gag virus like particles (VLPs) used as candidate vaccines are regarded as inert particles as they contain no replicative nucleic acid, although they do encapsidate cellular RNAs. During HIV-1 Gag VLP production in baculovirus-based expression systems, VLPs incorporate the baculovirus Gp64 envelope glycoprotein, which facilitates their entry into mammalian cells. This suggests that HIV-1 Gag VLPs produced using this system facilitate uptake and subsequent expression of encapsidated RNA in mammalian cells - an unfavourable characteristic for a vaccine. METHODS: HIV-1 Gag VLPs encapsidating reporter chloramphenicol acetyl transferase (CAT) RNA, were made in insect cells using the baculovirus expression system. The presence of Gp64 on the VLPs was verified by western blotting and RT-PCR used to detect and quantitate encapsidated CAT RNA. VLP samples were heated to inactivate CAT RNA. Unheated and heated VLPs incubated with selected mammalian cell lines and cell lysates tested for the presence of CAT protein by ELISA. Mice were inoculated with heated and unheated VLPs using a DNA prime VLP boost regimen. RESULTS: HIV-1 Gag VLPs produced had significantly high levels of Gp64 (~1650 Gp64 molecules/VLP) on their surfaces. The amount of encapsidated CAT RNA/μg Gag VLPs ranged between 0.1 to 7 ng. CAT protein was detected in 3 of the 4 mammalian cell lines incubated with VLPs. Incubation with heated VLPs resulted in BHK-21 and HeLa cell lysates showing reduced CAT protein levels compared with unheated VLPs and HEK-293 cells. Mice inoculated with a DNA prime VLP boost regimen developed Gag CD8 and CD4 T cell responses to GagCAT VLPs which also boosted a primary DNA response. Heating VLPs did not abrogate these immune responses but enhanced the Gag CD4 T cell responses by two-fold. CONCLUSIONS: Baculovirus-produced HIV-1 Gag VLPs encapsidating CAT RNA were taken up by selected mammalian cell lines. The presence of CAT protein indicates that encapsidated RNA was expressed in the mammalian cells. Heat-treatment of the VLPs altered the ability of protein to be expressed in some cell lines tested but did not affect the ability of the VLPs to stimulate an immune response when inoculated into mice. BioMed Central 2011-10-06 /pmc/articles/PMC3204299/ /pubmed/21975161 http://dx.doi.org/10.1186/1743-422X-8-462 Text en Copyright ©2011 Valley-Omar et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Valley-Omar, Ziyaad
Meyers, Ann E
Shephard, Enid G
Williamson, Anna-Lise
Rybicki, Edward P
Abrogation of contaminating RNA activity in HIV-1 Gag VLPs
title Abrogation of contaminating RNA activity in HIV-1 Gag VLPs
title_full Abrogation of contaminating RNA activity in HIV-1 Gag VLPs
title_fullStr Abrogation of contaminating RNA activity in HIV-1 Gag VLPs
title_full_unstemmed Abrogation of contaminating RNA activity in HIV-1 Gag VLPs
title_short Abrogation of contaminating RNA activity in HIV-1 Gag VLPs
title_sort abrogation of contaminating rna activity in hiv-1 gag vlps
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204299/
https://www.ncbi.nlm.nih.gov/pubmed/21975161
http://dx.doi.org/10.1186/1743-422X-8-462
work_keys_str_mv AT valleyomarziyaad abrogationofcontaminatingrnaactivityinhiv1gagvlps
AT meyersanne abrogationofcontaminatingrnaactivityinhiv1gagvlps
AT shephardenidg abrogationofcontaminatingrnaactivityinhiv1gagvlps
AT williamsonannalise abrogationofcontaminatingrnaactivityinhiv1gagvlps
AT rybickiedwardp abrogationofcontaminatingrnaactivityinhiv1gagvlps